LYSMD4 inhibitors belong to a unique class of compounds that specifically target the LysM domain-containing protein 4 (LYSMD4). LYSMD proteins are a subfamily of proteins characterized by the presence of the LysM (lysine motif) domain, which is commonly involved in protein-carbohydrate and protein-protein interactions. The LYSMD4 protein, in particular, is implicated in various cellular processes that involve the recognition and binding of specific carbohydrates or glycans. Inhibitors of LYSMD4 typically work by interfering with these interactions, thereby altering downstream signaling or biochemical pathways that depend on LYSMD4's role in cell communication or molecular recognition. The study of these inhibitors is essential for advancing our understanding of how carbohydrate-recognition motifs contribute to cellular function.
The chemical structure of LYSMD4 inhibitors is typically designed to mimic the binding interactions between LYSMD4 and its natural ligands, often involving molecular motifs that compete with carbohydrate-binding sites. These inhibitors often exhibit high specificity due to the precise interaction requirements of the LysM domain, making them ideal for probing the molecular mechanisms of LYSMD4 activity in biological systems. Researchers in structural biology and biochemistry focus on elucidating the binding kinetics and molecular geometry of these inhibitors, exploring how small modifications in the chemical structure can influence their ability to effectively bind to LYSMD4. By studying the intricate molecular dynamics of these inhibitors, scientists gain deeper insights into the complex regulatory networks that involve carbohydrate-binding domains, offering a wealth of information about cellular communication, molecular recognition, and biochemical pathway modulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
Can potentially regulate NF-kB pathways which may have crosstalk with LysM domain proteins. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Inhibitor of NF-kB activation, potentially interacting with LysM-related processes. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $33.00 $64.00 | 11 | |
NF-kB inhibitor that may influence LysM-associated activities. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
NF-kB nuclear translocation inhibitor, affecting LysM domain-related signaling. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $124.00 $526.00 | 55 | |
Inhibitor that impedes the cytokine-induced IκBα phosphorylation, potentially affecting LysM. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IKKβ inhibitor which can potentially intersect with LysM domain protein processes. | ||||||
ML 120B Dihydrochloride | 783348-36-7 (free base) | sc-487759 | 5 mg | $380.00 | ||
IKKβ-specific inhibitor, might affect pathways linked to LysM domain proteins. | ||||||
QNZ | 545380-34-5 | sc-200675 | 1 mg | $117.00 | 12 | |
Blocks NF-kB activation and might indirectly affect LysM-related signaling. | ||||||
Capsazepine | 138977-28-3 | sc-201098 sc-201098A | 5 mg 25 mg | $148.00 $459.00 | 11 | |
Blocks NF-kB activation and might influence LysM domain protein activities. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $110.00 $337.00 | 8 | |
IKK inhibitor that could intersect with pathways where LysM domain proteins play a role. | ||||||